Show simple item record

dc.contributor.authorBonthapally, V
dc.contributor.authorMa, E
dc.contributor.authorViviani, S
dc.contributor.authorRadford, John A
dc.contributor.authorBrice, P
dc.contributor.authorvon Tresckow, B
dc.contributor.authorThomas, E
dc.contributor.authorTeasell, J
dc.contributor.authorGnanasakthy, A
dc.contributor.authorOdom, D
dc.contributor.authorZhu, Y
dc.contributor.authorLee, S
dc.contributor.authorCarlson, P
dc.contributor.authorHuebner, D
dc.contributor.authorSweetenham, J
dc.contributor.authorMoskowitz, C
dc.contributor.authorWalewski, J
dc.date.accessioned2015-11-04T16:10:49Zen
dc.date.available2015-11-04T16:10:49Zen
dc.date.issued2015en
dc.identifier.citationBrentuximab Vedotin in Patients at Increased Risk of Hodgkin Lymphoma Progression Post Autologous Stem Cell Transplant: Evaluation of Healthcare Resource Utilization in the Aethera Trial. 2015, 100 579-580 Haematologicaen
dc.identifier.urihttp://hdl.handle.net/10541/581720en
dc.language.isoenen
dc.titleBrentuximab Vedotin in Patients at Increased Risk of Hodgkin Lymphoma Progression Post Autologous Stem Cell Transplant: Evaluation of Healthcare Resource Utilization in the Aethera Trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentTakeda Pharmaceuticalen
dc.identifier.journalHaematologicaen
dc.description.collectionLymphoma Research Teamen


This item appears in the following Collection(s)

Show simple item record